© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Oncologists Highlight Major Unanswered Questions Remaining for Approved CAR T Treatment in MCL
November 24, 2020
Investigators reported findings for 6 patients with mantle cell lymphoma who were treated in the ZUMA-2 clinical trial and progressed following treatment with therapy brexucabtagene autoleucel.
BTKi-Containing Triplet Active in Relapsed/Untreated Mantle Cell Lymphoma
November 23, 2020
Results from the study were published in Blood and showed that obinutuzumab plus ibrutinib and venetoclax as treatment of patients with relapsed and untreated mantle cell lymphoma achieved high response rates with favorable tolerability.
Exploring First-line Therapies in Peripheral T-Cell Lymphomas
November 23, 2020
During the Targeted Oncology Case Based Peer Perspectives event, Javier L. Munoz, MD, Hematologist/Oncologist Director, Lymphoma Program Mayo Clinic, discussed the case of 60-year-old patient with peripheral T-cell lymphoma.
ReSPECT Study Shows Positive Results in Recurrent Glioblastoma
November 23, 2020
The investigational drug Rhenium NanoLiposome demonstrated efficacy in an interim analysis presented at the 2020 Society for Neuro-Oncology Annual Meeting for patients with recurrent glioblastoma.
Treatment Options for Frontline CLL Merit In-depth Patient Discussions
November 23, 2020
During a Targeted Oncology Case Based Peer Perspective event, Erlene Seymour, MD, reviewed the front-line treatment options for chronic lymphocytic leukemia.
Despite Advances in Precision Medicine, Disparities Persist
November 23, 2020
The goal of precision medicine is to advance medical and scientific discoveries while offering more tailored, precise, and accurate health interventions, thus maximizing health benefits for patients while reducing adverse effects and overall cost of care.
Overcoming Widespread Effects of COVID-19 Calls for Resilience, Perseverance
November 22, 2020
The economic impact of the pandemic, which is still taking shape, will likely lead to many patients being uninsured, resulting in less access to medical care and ultimately culminating in an uptick in cancer-related mortality in the years ahead.
Many Oncologists Favor Consolidation Immunotherapy Following Chemoradiation for Stage III NSCLC
November 21, 2020
During a Targeted Oncology Case Based Peer Perspectives event, John Heymach, MD, PhD, professor and Chair, David Bruton Jr Chair in Cancer Research. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discussed the guidelines and therapeutic option for stage III non–small cell lung cancer, based on a case of a 66-year-old patient.
Pacritinib Demonstrates Potential to Fill Unmet Need in Myelofibrosis
November 21, 2020
John O. Mascarenhas, MD, discusses pacritinib for patients with myelofibrosis and thrombocytopenia.
Incorporating Genomics into Lymphoma Classification Can Improve Care
November 21, 2020
The incorporation of genomics into the classification and treatment decision-making process for lymphomas is possible; however, many obstacles have prevented the incorporation of sequencing into standard practice, according to Sandeep Dave, MD.
Big Data–Based Tools Support Cancer Clinical Decision-Making
November 20, 2020
Clinicians are increasingly looking to big data and electronic medical records (EMR) data integration tools in support of clinical decision-making questions and processes for improved access and care for their patients with cancer.
Using Comprehensive Genomic Profiling to Identify Rare Subsets of Merkel Cell Carcinoma
November 20, 2020
Ryan C. DeCoste, MD, discusses how comprehensive genomic profiling can be used to identify rare subsets of patients with Merkel cell carcinoma.